The main markets for the supply of the Russian Sputnik V coronavirus vaccine are the Middle East, Africa, Asia and Latin America. There are geopolitical restrictions when working with Europe and the United States, said Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), which took part in the development of the drug.
We are absolutely realistic that due to geopolitical restrictions, supplies to the United States and Europe will be limited, although <...> we could also supply allergy sufferers, – he said.
According to him, Russian developers plan to move to the European market “gradually”. At the same time, RDIF will receive income from the sale of the drug to other countries.
Of course, we are paid for this vaccine, we, as a state fund, as a sovereign fund of the Russian Federation, will receive funds for the supply of vaccines abroad, – noted he is on the air of the Russia 24 TV channel.
However, the priority remains the supply of vaccines for Russians, since at the moment there are not enough such drugs in the world. In this regard, medicines for delivery abroad will be produced at foreign sites. Thus, on December 29, RDIF received the first batch of Sputnik V, manufactured in South Korea.
Currently, two vaccines against coronavirus have been registered in Russia: Sputnik V (developed by the Gamaleya Center) and EpiVacCorona (created at the Vector Center). Soon, registration of the third drug is possible, on which specialists of the Chumakov Center of the Russian Academy of Sciences are working.
chernayakobra.ru previously wrote that the head of the Turkish Foreign Ministry, Mevlut Cavusoglu, spoke about the cooperation between Turkey and Russia on the Sputnik V coronavirus vaccine.
According to him, during the meeting of the Council of Ministers, which took place on 28 December, Turkish Health Minister Fahrettin Koca said that the relevant work “is going on in a normal way.”